Anti-IL17 antibody secukinumab therapy is associated with ossification in giant cell tumor of bone: A case report of pathologic similarities and therapeutic potential similar to denosumab Journal Article


Authors: Chandler, A.; Bartelstein, M. K.; Fujiwara, T.; Antonescu, C. R.; Healey, J. H.; Vaynrub, M.
Article Title: Anti-IL17 antibody secukinumab therapy is associated with ossification in giant cell tumor of bone: A case report of pathologic similarities and therapeutic potential similar to denosumab
Abstract: Background: Giant cell tumor of bone is a benign, locally aggressive neoplasm. Surgical resection is the preferred treatment method. However, for cases in which resection poses an increased risk to the patient, denosumab (anti-RANKL monoclonal antibody) is considered. Secukinumab is an anti-IL-17 antibody that is used in psoriatic arthritis to reduce bone resorption and articular damage. Case presentation: One case of giant cell tumor of bone (GCTB) in a patient treated with secukinumab for psoriatic arthritis demonstrated findings significant for intra-lesional calcifications. Histologic examination showed ossification, new bone formation, and remodeling. A paucity of osteoclast type giant cells was noted. Real-time quantitative polymerase-chain-reaction (qRT-PCR) analysis revealed decreased osteoclast function compared to treatment-naive GCTB. Conclusions: Secukinumab may play a role in bone remodeling for GCTB. Radiologists, surgeons, and pathologists should be aware of this interaction, which can cause lesional ossification. Further research is required to define the therapeutic potential of this drug for GCTB and osteolytic disease. © 2021, The Author(s).
Keywords: case report; egfr; denosumab; rankl; il-17; gctb; osteoprogeterin; secukinumab
Journal Title: BMC Musculoskeletal Disorders
Volume: 22
ISSN: 1471-2474
Publisher: Biomed Central Ltd  
Date Published: 2021-04-01
Start Page: 320
Language: English
DOI: 10.1186/s12891-021-04182-z
PUBMED: 33794838
PROVIDER: scopus
PMCID: PMC8015053
DOI/URL:
Notes: Article -- Export Date: 3 May 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Cristina R Antonescu
    897 Antonescu
  2. John H Healey
    550 Healey
  3. Maksim Vaynrub
    36 Vaynrub